Clinical Trial Goal
To find out:
- The highest dose of ZE46-0134 that's safe to give
- If ZE46-0134 is safe and works well to treat FLT3+ AML or AML with spliceosome mutation
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML
- Have cancer cells with any of the following mutations. Your doctor can tell you this:
- FLT3
- SF3B1
- SRSF2
- U2AF1
- ZRSR2
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ZE46-0134 is a small molecule inhibitor that blocks FLT3 and IRAK4 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle you'll get:
- ZE46-0134 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for 2 years. You'll have biopsies to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved ZE46-0134.
Locations
Sponsors
lead: Lomond Therapeutics Holdings, Inc.

